Tech Company Financing Transactions

Syremis Therapeutics Funding Round

On 12/18/2025, Syremis Therapeutics raised $165 million in Series A funding from Dexcel Pharma, Third Rock Ventures and Bain Capital Life Sciences.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Undisclosed
Boston, MA Undisclosed
USA

Phone

Undisclosed

Website

www.syremis.com

Email Address

[email protected]

Overview

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health. The company's neuropsychiatric pipeline is rooted in emerging and clinically validated mechanisms, including muscarinic M1/M4 agonism and next-generation NMDA antagonism.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Elisabeth Kogan

        

Browse more venture capital transactions:

Prev: 12/18/2025: Cowboy venture capital transaction
Next: 12/18/2025: Atavistik Bio venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary